曲妥珠单抗联合顺铂治疗HER2阳性乳腺癌患者临床观察

Clinical observation of trastuzumab combined with cisplatin in the treatment of patients with HER2 positive breast carcinoma

目的观察曲妥珠单抗联合顺铂治疗人表皮生长因子受体2(HER2)阳性乳腺癌患者的临床疗效。方法选取2016年1月至2018年1月在我院接受乳腺癌改良根治术治疗的HER2阳性乳腺癌女性患者65例为研究对象,按术后化疗方案将患者分为两组,对照组患者(30例)术后给予顺铂化疗,试验组患者(35例)术后给予曲妥珠单抗联合顺铂化疗,比较两组患者的临床疗效及远期生存率。结果完成4~6个周期化疗后,试验组患者的治疗总有效率(82.86%)明显高于对照组(56.67%),差异有统计学意义(P<0.05)。疗程结束后,试验组患者健康调查简表(SF-36)的各维度评分均明显高于对照组,差异有统计学意义(P<0.05)。疗程结束后对患者进行3年随访分析发现,试验组患者的死亡率(31.4%)明显低于对照组(63.3%),无进展生存率(60.0%)明显高于对照组(26.7%),差异有统计学意义(P<0.05)。结论曲妥珠单抗联合顺铂化疗能显著提高HER2阳性乳腺癌患者的临床疗效、生活质量及术后生存率,对临床治疗具有重要的参考价值。

Objective To observe the clinical efficacy of trastuzumab combined with cisplatin in the treatment of patients with human epidermal growth factor receptor 2(HER2)positive breast carcinoma.Methods A total of 65 patients with HER2 positive breast carcinoma who received modified radical mastectomy in our hospital from January 2016 to January 2018 were selected as the research objects,and they were divided into two groups according to the postoperative chemotherapy regimen.The control group(30 cases)was given cisplatin chemotherapy after operation,and the experimental group(35 cases)was treated with trastuzumab combined with cisplatin chemotherapy after operation.The clinical efficacy and long-term survival rate were compared between the two groups.Results After 4 to 6 cycles of chemotherapy,the total effective rate of treatment of the experimental group(82.86%)was significantly higher than that of the control group(56.67%),with a statistically significant difference(P<0.05).After the treatment courses,the scores of all dimensions of the mos 36-item short form health survey(SF-36)in the experimental group were significantly higher than those in the control group,with statistically significant differences(P<0.05).After the treatment courses,3-year follow-up analysis of the patients showed that the mortality of the experimental group(31.4%)was significantly lower than that of the control group(63.3%),and the progression-free survival rate(60.0%)was significantly higher than that of the control group(26.7%),with statistically significant differences(P<0.05).Conclusion Trastuzumab combined with cisplatin chemotherapy can significantly improve the clinical efficacy,quality of life and postoperative survival rate of patients with HER2 positive breast carcinoma,which has important reference value for clinical treatment.